Alterations of Plasma Metabolites Associated with Sickle Cell Trait.

KEY POINTS: We identified 69 plasma metabolites associated with sickle cell trait, including markers of eGFR and/or related to oxidative stress pathways. Twenty-five percent or 39% of the sickle cell trait-associated metabolites were replicated in the Atherosclerosis Risk in Communities study. Sickle cell trait-associated metabolites individually or in aggregate were associated with better prediction of incident kidney failure in those with sickle cell trait.

BACKGROUND

Sickle cell trait (SCT) is the heterozygous carrier state for sickle cell disease (SCD) and is common among individuals of African ancestry. Although SCT is a known risk factor for CKD and ESKD, the mechanisms underlying this phenotypic association have not been fully characterized. We used metabolomic profiling to gain insight into the pathobiology of SCT.

METHODS

We used a nontargeted metabolomics approach (Metabolon Global Discovery Panel) to measure baseline plasma levels of 851 metabolites in 986 older Black women with SCT (mean age 61±7 years) compared with 998 age- and race-matched controls without SCT from the prospective Women's Health Initiative (WHI) study. Age-adjusted linear regression was used to assess the association between metabolite levels and SCT. Replication was performed in an independent sample of 1070 Black men and women (including 70 with SCT) from the Atherosclerosis Risk in Communities study.

RESULTS

In age-adjusted models, 69 metabolites were significantly associated with SCT in WHI after correction for multiple testing. Many of the SCT-associated metabolites are markers of kidney glomerular filtration (eGFR) and/or related to oxidative stress metabolic pathways are known to be altered in SCD homozygotes. Of the 64 SCT-associated metabolites available for replication, 25 or 39% were replicated in the Atherosclerosis Risk in Communities study. Inclusion of SCT-associated metabolites was associated with significantly better risk prediction of incident ESKD in WHI among SCT individuals compared with a baseline model adjusted for age+eGFR.

CONCLUSIONS

We identified and replicated metabolites associated with SCT, many of which are related to eGFR and/or pathways altered in SCD ( e.g ., oxidative stress, membrane remodeling). These results suggest that plasma metabolomic profiling may be useful in ESKD risk stratification for individuals with SCT, meriting validation in larger cohorts.